References
- BatraASAlexanderMESilkaMJAttention-defcit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reasonPediatr Cardiol20123339440122298228
- FerrinMVanceAExamination of neurological subtle signs in ADHD as a clinical tool for the diagnosis and their relationship to spatial working memoryJ Child Psychol Psychiatry20125339040022141455
- McDonaghMSPetersonKThakurtaSLowADrug class review: pharmacologic treatments for attention deficit hyperactivity disorder: final update 4 reportPortland, OROregon Health and Science University2011 Available from: http://www.ncbi.nlm.nih.gov/books/NBK84419/. Accessed November 24, 2012.
- MayDEKratochvilCJAttention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapyDrugs201070154020030423
- FindlingRLEvolution of the treatment of attention-deficit/ hyperactivity disorder in children: a reviewClin Ther20083094295718555941
- DuongSChungKWigalSBMetabolic, toxicological, and safety considerations for drugs used to treat ADHDExpert Opin Drug Metab Toxicol2012854355222413882
- LeeJGrizenkoNBhatVSenguptaSPolotskaiaAJooberRRelation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHDBMC Psychiatry2011117021510895
- SadeeWGenomics and personalized medicineInt J Pharm2011302421539903
- EvansWERellingMVPharmacogenomics: translating functional genomics into rational therapeuticsScience199928648749110521338
- LooTTRossCJSistonenJPharmacogenomics and active surveillance for serious adverse drug reactions in childrenPharmacogenomics2010111269128520860467
- ZangerUMRaimundoSEichelbaumMCytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistryNaunyn Schmiedebergs Arch Pharmacol2004369233714618296
- BrockmöllerJKirchheinerJMeiselCRootsIPharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatmentPharmacogenomics2000112515111256586
- Ingelman-SundbergMGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics J2005561315492763
- KirchheinerJRodriguez-AntonaCCytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disordersCNS Drugs20092318119119320528
- SeeringerAKirchheinerJPharmacogenetics-guided dose modifcations of antidepressantsClin Lab Med20082861962619059066
- ZhouSFPolymorphism of human cytochrome P450 2D6 and its clinical significance: Part IClin Pharmacokinet20094868972319817501
- OtaniKAoshimaTPharmacogenetics of classical and new antipsychotic drugsTher Drug Monit20002211812110688273
- MurrayMRole of CYP pharmacogenetics and drug–drug interactions in the effcacy and safety of atypical and other antipsychotic agentsJ Pharm Pharmacol20065887188516805946
- BhudisriSAttention and disruptive behavior disorderPsychiatry, Ramathibodi Hospital, Psychiatry, Faculty of Medicine, Ramathibodi Hospital, Mahidol University2005 Available from http://www.rama-mental.com/medicalstudent/childandteen/attention_deficit_disorder/. Accessed December 15, 2012Thai.
- HongsanguansriSAttention deficit hyperactivity disorder (ADHD). How to take care patients who have the psychiatry or mental health problems. Physician’s guidelineDepartment of Mental Health2001 Available from: http://www.ramamental.com/gp/gp24.PDF . Accessed December 15, 2012 Thai.
- Bonnet-BrilhaultFBrolyFBlancRFuretYBarthélémyCPaintaudGAn ADHD 6-year-old child ultrarapid metabolizer for CYP2D6J Clin Psychopharmacol20062644244416855474
- WuDOttonSVInabaTKalowWSellersEMInteractions of amphetamine analogs with human liver CYP2D6Biochem Pharmacol199753160516129264312
- DeVaneCLMarkowitzJSCarsonSWSingle-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizersJ Clin Psychopharmacol20002034734910831022
- MarkowitzJSPatrickKSPharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorderClin Pharmacokinet20014075377211707061
- HunninghakeDStudies of the inhibition of drug metabolism by methylphenidate [Abstract]Fed Proc197029345
- SmithDAJonesBCSpeculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymesBiochem Pharmacol199244208920981472073
- BertilssonLDahlMLDalenPAl-ShurbajiAMolecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsBr J Clin Pharmacol20025311112211851634
- LamYWGaedigkAEreshefskyLAlfaroCLSimpsonJCYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6Pharmacotherapy2002221001100612173784